Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Location: United States, Massachusetts, Cambridge
Total raised: $60M
Investors 3
| Date | Name | Website |
| 23.10.2020 | Alta Partn... | altapartne... |
| - | RA Capital... | racap.com |
| - | Atlas Vent... | atlasventu... |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 26.10.2020 | Series A | $52M | - | finsmes.co... |
| 10.09.2012 | Series A | $8M | - | vcnewsdail... |
Mentions in press and media 6
| Date | Title | Description | Category | Author | Source |
| 26.10.2020 | Be Biophar... | Be Biopharma, a Cambridge, MA-... | USA | - | finsmes.co... |
| 26.10.2020 | StartUPDAT... | “To break the cost curve for b... | - | - | medcitynew... |
| 10.09.2012 | Annovation... | CAMBRIDGE, MA, Biotechnology... | - | - | vcnewsdail... |
| 10.09.2012 | Annovation... | Annovation Biopharma, a Waylan... | Uncategori... | - | finsmes.co... |
| - | StartUPDAT... | Bind announced a $105 million ... | - | - | medcitynew... |
| - | Be Bio Ann... | CAMBRIDGE, Mass.--(BUSINESS WI... | - | - | oaoa.com/n... |